Gain Therapeutics reports preclinical data n GT-02287

Gain Therapeutics (GANX) announced that a guided poster presentation was made at the International Association of Parkinsonism and Related Disorders 30th World Congress on Parkinson’s Disease and Related Disorders, held May 7th-10th in New York City, NY. The poster outlined new evidence supporting GT-02287’s ability to provide a broader neuroprotective effect and potential as a disease-modifying therapy for Parkinson’s disease. Title: GT-02287, A Clinical-stage Allosteric GCase Modulator For The Treatment Of Parkinson’s Disease, Protects Dopaminergic Neurons Against Mitochondrial Toxin MPP+ Summary: In cultured rat mesencephalic dopaminergic neurons treated with MPP+, a mitochondrial toxin that induces mitochondrial impairment by inhibiting mitochondrial complex 1, GT-02287 improved the function of both the lysosomes and mitochondria and exerted a broader neuroprotective effect. GT-02287 lowered alpha-synuclein aggregation, lysosomal dysfunction, and mitochondrial stress while also preventing the release of mitochondrial cytochrome C, a programmed cell death signal, thereby promoting neuronal survival.